SBIR/STTR Research Award

Ultrasound Catheter for Guiding and Effecting Neointimal Hyperplasia Prevention

Award identifier fc9aff984e368807c178565dff1f93ea14ee819c1c9a7b8274f407c12ba7cfebAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$264,881

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SoundPipe, LLC
Proposal award date
2014-12-01
Contract end date
2016-05-03
UEI
JLYJYPLD1LV7
Solicitation number
PA16-019
Topic code
NHLBI

Research abstract

DESCRIPTION provided by applicant In the treatment of acute artery disease percutaneous interventions using drug eluting stents are the preferred method of treatment Although effective for simple conditions e g short lesions single vessels when treating tortuous or bifurcating vessels drug eluting stents can provide incomplete drug coverage resulting in neointimal hyperplasia or acute thrombosis The fixed dose and drug choice of the drug eluting stent also limits the physicianandapos s ability to tailor treatment to the patientandapos s individal need Further current methods rely on angiography for verification and quantification of successful angioplasty and stent deployment Angiography provides no information regarding lumen diameter and plaque composition In order to address these needs SoundPipe is developing a flexible combined ultrasound imaging and therapy CUIT or theranostic catheter and control system for ultrasound and microbubble enhanced delivery of antiproliferative agents This approach will use a andquot Detect Displace Deliverandquot D therapy model to guide and effect therapy Following balloon angioplasty the lesion will be detected using intravascular ultrasound to verify catheter placement for drug delivery Then sirolimus i e rapamycin bearing microbubbles will be infused through the catheter and localized to the vessel wall using ultrasound Once the therapeutic microbubbles have been localized along the injured vessel wall the combination of low frequency ultrasound and microbubbles will transiently permeabilize the cell membrane This will cause delivery of the sirolimus from the microbubble shell enabling localized therapy This method may improve treatment of acute coronary events by enabling localized drug delivery independent of a mechanical delivery platform e g balloon or stent enabling on site control of drug dose and enhancing drug uptake with the potential to reduce drug doses This Phase I SBIR seeks to demonstrate that a CUIT catheter can provide D therapy for localized drug delivery and imaging feedback within a blood vessel In order to prove this hypothesis a Form Fit and Function prototype of a CUIT catheter and control system will be designed and developed to perform both low frequency microbubble based therapy and high frequency imaging Key technological innovations will be achieved in the integration of a therapeutic and high resolution IVUS system With the proposed CUIT IVUS catheter system in place system parameters will be optimized to maximize model drug delivery with the SoundPipe system in an ex vivo swine artery model Plans for Phase II include user interface development for the IVUS drug delivery system and an in vivo swine model study of system efficacy PUBLIC HEALTH RELEVANCE In the treatment of acute artery disease percutaneous interventions using drug eluting stents are the preferred method of treatment Although effective for simple conditions e g short lesions single vessels when treating tortuous or bifurcating vessels drug eluting stents can provide incomplete drug coverage fixed drug dose and fixed drug choice which limits the physicianandapos s ability to tailor treatment to the patientandapos s individual ned The long term goal of this project is to provide interventional cardiologists with a more versatile and effective platform for treating lesions following PCI that incorporates detection and therapy in one platform providing real time feedback throughout therapy and thus potentially improving patient outcomes

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2015–2018). Reported award amounts total $3,275,458. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.